Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immune response modulation by pentoxifylline in vitro

H Tilg1, B Eibl, M Pichl

  • 1Department of Internal Medicine, University Hospital, Innsbruck, Austria.

Transplantation
|July 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

T-cell precursor frequencies and long-term outcome following unrelated hematopoietic stem cell transplantation.

International journal of laboratory hematology·2008
Same author

Comparison of total and partial traumatic tears of the subscapularis tendon.

The Journal of bone and joint surgery. British volume·2005
Same author

[Limitation of shoulder mobility due to ankylosis of the sternoclavicular joint in SAPHO syndrome].

Der Orthopade·2003
Same author

[Treatment of trochanteric fractures with the gamma nail].

Der Unfallchirurg·2003
Same author

Survival after bone marrow transplantation from cytomegalovirus seropositive sibling donors.

Lancet (London, England)·2001
Same author

[Diagnosis and stage-related therapy of joint infections].

Der Unfallchirurg·2001

Pentoxifylline (PTX) significantly suppresses immune cell proliferation and cytokine production in vitro, offering potential benefits for managing bone marrow transplant complications. This study details PTX

Area of Science:

  • Immunology
  • Pharmacology
  • Transplantation Medicine

Background:

  • Pentoxifylline (PTX) has demonstrated efficacy in mitigating bone marrow transplant (BMT) complications by modulating tumor necrosis factor-alpha (TNF-alpha) production.
  • Understanding the detailed immunomodulatory effects of PTX on immune responses is crucial for optimizing its therapeutic application post-BMT.

Purpose of the Study:

  • To investigate the in vitro immunomodulatory effects of Pentoxifylline (PTX) on various immune responses relevant to bone marrow transplant (BMT) complications.
  • To elucidate the mechanisms underlying PTX's immunomodulatory actions, including its impact on cytokine production and cellular proliferation.

Main Methods:

  • Assessed the effect of PTX on peripheral blood mononuclear cell (PBMC) proliferation stimulated by mitogens and alloantigens using dose-dependent assays.

Related Experiment Videos

  • Evaluated PTX's impact on cytotoxic T lymphocyte (CTL) generation via cell-mediated lymphotoxicity assays and on natural killer (NK) cell activity.
  • Quantified mRNA expression and protein levels of TNF-alpha, IFN-gamma, neopterin, IFN-alpha, IL-1 beta, and IL-6 in PTX-treated cultures.

    • Main Results:

    • PTX significantly inhibited PBMC proliferation in a dose-dependent manner, completely blocking mitogen-induced proliferation at 1000 micrograms/ml.
    • PTX suppressed the in vitro generation of CTLs and reduced NK cell specific lysis, with maximal effects observed at higher concentrations.
    • Immunomodulation by PTX was linked to decreased TNF-alpha and IFN-gamma production, but not IFN-alpha or IL-1 beta; IL-6 release was increased.

    Conclusions:

    • Pentoxifylline exhibits significant in vitro immunomodulatory properties, selectively inhibiting certain cytokine releases and cellular functions.
    • PTX's effects are partly mediated by TNF-alpha modulation but involve broader impacts on immune cell responses.
    • These findings support PTX's potential as a therapeutic agent for managing immune-related complications following bone marrow transplantation.